Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
6.90
+0.32 (4.95%)
Oct 31, 2025, 3:11 PM EDT - Market open
Organon & Co. Revenue
Organon & Co. had revenue of $1.59B in the quarter ending June 30, 2025, a decrease of -0.81%. This brings the company's revenue in the last twelve months to $6.28B, down -1.02% year-over-year. In the year 2024, Organon & Co. had annual revenue of $6.40B with 2.24% growth.
Revenue (ttm)
$6.28B
Revenue Growth
-1.02%
P/S Ratio
0.27
Revenue / Employee
$628,100
Employees
10,000
Market Cap
1.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.40B | 140.00M | 2.24% |
| Dec 31, 2023 | 6.26B | 89.00M | 1.44% |
| Dec 31, 2022 | 6.17B | -130.00M | -2.06% |
| Dec 31, 2021 | 6.30B | -228.00M | -3.49% |
| Dec 31, 2020 | 6.53B | -1.25B | -16.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
OGN News
- 3 days ago - The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products - Seeking Alpha
- 3 days ago - Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman - GlobeNewsWire
- 4 days ago - Organon CEO Kevin Ali to resign after probe into wholesaler sales practices - Reuters
- 4 days ago - Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation - Business Wire
- 14 days ago - Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy - Seeking Alpha
- 6 weeks ago - European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Business Wire
- 2 months ago - US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Business Wire
- 2 months ago - Organon: Valuation Discount Offset By Structural Headwinds - Seeking Alpha